HUTCHMED (CHINA) LTD (HCM)
HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
📈 **POSITIVE** • Medium confidence analysis (68%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (82%) **Content type:** Clinical